Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
11 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03625388 | Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | completed | Phase 2 | 56 | Hikma Pharmaceuticals LLCINDUSTRY | 4 | Sep 22, 2023 | clinicaltrials |
| NCT05868317 | Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer | unknown | Phase 2 | 70 | Salah Azaïz Cancer InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT02269943 | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 36 | CelgeneINDUSTRY | 9 | Dec 12, 2018 | clinicaltrials |
| NCT00111787 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | completed | Phase 2 | 49 | GlaxoSmithKlineINDUSTRY | 9 | May 31, 2017 | clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT01325428 | Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer | completed | Phase 2 | 26 | Boehringer IngelheimINDUSTRY | 7 | Jul 19, 2016 | clinicaltrials |
| NCT00105950 | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer | completed | Phase 2 | 126 | GlaxoSmithKlineINDUSTRY | 8 | Sep 28, 2015 | clinicaltrials |
| NCT00565448 | Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents | completed | Phase 2 | 75 | SanofiINDUSTRY | 14 | Jul 30, 2015 | clinicaltrials |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | completed | Phase 2 | 163 | GlaxoSmithKlineINDUSTRY | 28 | Feb 4, 2013 | clinicaltrials |
| NCT00485979 | Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients(SATIN) | completed | Phase 2 | 330 | SanofiINDUSTRY | 8 | Jun 28, 2011 | clinicaltrials |
| NCT00916097 | NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT) | completed | Phase 2 | 66 | SanofiINDUSTRY | 3 | Jun 24, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials